Properties		Conclusion (a)
CMR	Carcinogenicity (C)	Isoflucypram is not considered likely to be carcinogenic to human according to point 3.6.3 of Annex II of Regulation (EC) 1107/2009
	Mutagenicity (M)	Isoflucypram is not considered likely to be genotoxic to human according to point 3.6.2 of Annex II of Regulation (EC) 1107/2009
	Toxic for Reproduction (R)	Isoflucypram is classified as reproductive toxicant category 2, and not category 1A or 1B according to point 3.6.4 of Annex II of Regulation (EC) 1107/2009
Endocrine‐disrupting properties		The endocrine disruption properties of isoflucypram for the T‐modality for humans according to points 3.6.5 and 3.8.2 of Annex II of Regulation No 1107/2009, as amended by Commission Regulation (EU) 2018/605 cannot be concluded. Isoflucypram is not considered to meet the criteria for endocrine disruption for the EAS modalities for humans and non‐target organisms according to points 3.6.5 and 3.8.2 of Annex II of Regulation No 1107/2009, as amended by Commission Regulation (EU) 2018/605.
POP	Persistence	Isoflucypram is not considered to be a persistent organic pollutant (POP) according to point 3.7.1 of Annex II of Regulation (EC) 1107/2009.
	Bioaccumulation
	Long‐range transport
PBT	Persistence	Isoflucypram not considered to be a persistent, bioaccumulative and toxic (PBT) substance according to point 3.7.2 of Annex II of Regulation (EC) 1107/2009.
	Bioaccumulation
	Toxicity
vPvB	Persistence	Isoflucypram not considered to be a very persistent, very bioaccumulative substance according to point 3.7.3 of Annex II of Regulation (EC) 1107/2009.
	Bioaccumulation

^(a)Origin of data to be included where applicable (e.g. EFSA, ECHA RAC, Regulation).